# STORM Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/storm-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.stormtherapeutics.com
- Total disclosed funding: $185M
- Latest round: Series C (Nov 3, 2026)
- Investors on record: 11

## About

Founded in 2015, STORM Therapeutics Limited f.k.a., Iceni Therapeutics Limited, based in the UK, specializes in developing innovative small molecule therapies that target RNA modifying enzymes, focusing on oncology and other disease areas.STORM Therapeutics Limited is engaged in the development of RNA modifying enzyme therapies. The company, headquartered in England, UK, was co-founded by Tony Kouzarides and Eric Miska. In April 2026, STORM Therapeutics Limited raised USD 56 million in series C funding from M Ventures, Pfizer Venture Investments, Taiho Ventures, IP Group, UTokyo Innovation Platform, and Fast Track Initiative. STORM Therapeutics specializes in developing small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. Their lead product, STC-15, is a first-in-class METTL3 inhibitor aimed at enhancing cancer treatment efficacy by disrupting specific RNA modification pathways, targeting primarily healthcare providers and oncologists in North America and Europe.For the most recent year, STORM Therapeutics reported a revenue of GBP 9,118,484.90, with an EBITDA of GBP -17,003,586.90, operating through partnerships and collaborations in the biotechnology and pharmaceutical sectors to generate income from co-development agreements and licensing of proprietary therapies. The company will use the April 2026 funding to advance STC-15 into Phase 2 monotherapy studies in selected sarcoma indications and support broader oncology development.

## Funding rounds

- Series C, Nov 3, 2026, $56M — M Ventures, Pfizer Ventures
- Series C, Apr 5, 2026, $56M — M Ventures, Pfizer Venture Investments, Taiho Ventures, Fast Track Initiative, UTokyo Innovation Platform, IP Group
- Series B, May 27, 2022, $33M — Seroba, Longview Innovation, Pfizer Venture Investments, Cambridge Innovation Capital, Fast Track Initiative, UTokyo Innovation Platform, M Ventures
- Series A, May 24, 2019, $18M — Seroba, Longview Innovation, Pfizer Venture Investments, Cambridge Innovation Capital, Taiho Ventures, M Ventures
- Series A, Jul 17, 2018, $7M — Taiho Ventures
- Series A, Jun 15, 2016, $16M — Pfizer Venture Investments, Touchstone Innovations, Cambridge Innovation Capital
- Seed, May 1, 2015 — Touchstone Innovations

## Investors

- Touchstone Innovations (https://capitalatlas.ai/funds/touchstone-innovations) — Seed, Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A, Series B, Series C
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Series A, Series B
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series A, Series C
- Seroba (https://capitalatlas.ai/funds/seroba) — Series A, Series B
- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series A, Series B
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A, Series B, Series C
- Fast Track Initiative (https://capitalatlas.ai/funds/fast-track-initiative) — Series B, Series C
- UTokyo Innovation Platform (https://capitalatlas.ai/funds/utokyo-innovation-platform) — Series B, Series C
- IP Group — Series C
- Pfizer Ventures — Series C